GlassScriptPhysician profile
Timothy C Foster
NPI 1740244995
$4,033.48
in general payments reported to CMS, 2019-2025
25 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,701 · 2020: $80.01 · 2021: $119 · 2022: $236 · 2023: $659 · 2024: $877 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,683 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.59 |
| Education | $214.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,266.29 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $474.74 | 2022-2025 | Epidiolex |
| Supernus Pharmaceuticals, INC. | $336.14 | 2024-2025 | Qelbree |
| Ucb, INC. | $316.65 | 2022-2025 | Fintepla, Briviact |
| Greenwich Biosciences, INC. | $258.05 | 2019-2020 | |
| Biogen, INC. | $201.63 | 2019-2024 | Spinraza |
| Ironshore Pharmaceuticals INC. | $171.06 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $152.56 | 2019-2021 | |
| Eisai INC. | $147.23 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $130.34 | 2023-2025 | Daybue |
| Sumitomo Pharma America, INC. | $75.60 | 2023 | Aptiom |
| Zogenix INC. | $63.03 | 2021 | |
| Immedica Pharma US, INC. | $60.76 | 2023 | |
| Aquestive Therapeutics, INC. | $47.20 | 2024-2025 | |
| Neurelis, INC. | $45.79 | 2025 | Valtoco |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sarepta Therapeutics, INC. | $45.31 | 2022-2024 | Elevidys |
| Neuropace, INC. | $42.76 | 2023-2025 | |
| Harmony Biosciences LLC | $40.22 | 2025 | |
| Springworks Therapeutics, INC. | $31.04 | 2025 | Gomekli |
| Amneal Pharmaceuticals LLC | $27.89 | 2023 | Lyvispah |
| Corium, LLC | $23.84 | 2024 | Azstarys |
| Biomarin Pharmaceutical INC. | $19.99 | 2021 | |
| Genzyme Corporation | $19.54 | 2019 | |
| Sunovion Pharmaceuticals INC. | $18.81 | 2022 | |
| Metacel Pharmaceuticals LLC | $17.01 | 2024 | Ozobax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.